

Growth across markets ; maintain Buy

We maintain our Buy rating on Aurobindo Pharma (APL) and revise TP to Rs1,070 (earlier Rs1,170) based on 18x March'20E EPS of Rs59.3. The company's Q4FY18 revenues and net profit were in-line with our expectations. However, EBITDA margin was below expectation. APL's sales grew 11% YoY, margin improved 10bps to 19.9%, and net profit declined by 1% YoY. APL's two manufacturing units IV and XII have been cleared and received EIR from US FDA. Its specialised segments such as injectables, penam, microspheres, hormones, oncology, vaccines, neutraceutical, depot injections and peptides would improve margins due to complexity in the manufacturing. APL has developed a robust pipeline of 478 ANDAs for the US market through differentiated products. APL is among our top picks in the pharma sector.

- **EU formulations-good growth:** APL's formulations business' revenue (80% of total) grew 11% YoY to Rs40.49bn from Rs36.42bn. Its US-based formulations business (43% of revenues) grew by 6%YoY to Rs17.39bn from Rs16.43bn. Formulations in the EU (28% of revenues) grew 48% YoY to Rs11.52bn from Rs7.77bn due to the integration of the acquired Portuguese business. The emerging market formulations business (5% of revenues) grew by 6%YoY to Rs2.10bn. The company's API business (20% of revenues) grew by 5% to Rs7.99bn. The management expects new product launches, volume growth of existing products and good growth of injectable business in the US.
- **Margins improved by 10bps YoY:** APL's EBITDA margins improved 10bps YoY to 19.9% from 19.8% due to the reduction in material cost and other expenses. Its material cost declined by 10bps to 41.2% from 41.3% due to the change in product mix. Personnel expenses grew 170bps to 14.4% from 12.7% due to Portuguese acquisition. Other expenses declined 160bps to 24.6% from 26.2%. We expect new product launches, ARV tender supplies, controlled substances, neutraceutical and the injectable businesses in the US to aid in margin improvement.
- **Net profit declined 1%YoY:** APL's net profit declined by 1% YoY to Rs5.29bn from Rs5.32bn. The company's tax rate enhanced to 18.8% from 18.1% of PBT. Other income grew by 101% to Rs218mn from Rs438mn. We expect its net profit to grow further led by expected revenue growth and margin improvement.
- **Attractive valuations and key risks:** We maintain our Buy rating on the scrip, with a TP of Rs1,070 based on 18x March'20E EPS of Rs59.3, and with an upside of 99.9% from CMP. We have revised our FY19E and FY20E EPS downwards by 14% and 8% respectively. APL is among our top picks in the pharma sector. Key risks to our assumptions include slower growth in the US business and regulatory risks for its manufacturing facilities.

Particulars (Rs mn)	Q4FY18	Q4FY17	YoY (%)	Q3FY18	QoQ (%)	Q4FY18E	% Var.
Total Revenues	40,491	36,416	11.2	43,361	(6.6)	42,502	(4.7)
Raw material cost	16,694	15,028	11.1	18,175	(8.1)	17,400	(4.1)
Employee cost	5,813	4,635	25.4	5,407	7.5	5,500	5.7
Other expenses	9,943	9,541	4.2	9,524	4.4	9,750	2.0
EBIDTA	8,041	7,212	11.5	10,255	(21.6)	9,852	(18.4)
EBIDTA margin (%)	19.9	19.8	-	23.7	-	23.2	-
Depreciation	1,566	1,001	56.4	1,381	13.4	1,450	8.0
Interest	247	143	72.7	189	30.7	170	45.3
Other income	438	218	100.9	331	32.3	370	18.4
PBT	6,507	6,476	0.5	9,016	(27.8)	8,632	(24.6)
Prov. For tax	1,224	1,171	4.5	3,069	(60.1)	3,050	(59.9)
Adj. PAT	5,286	5,324	(0.7)	5,950	(11.2)	5,590	(5.4)

Source: Company, Centrum Research Estimates

Y/E Mar (Rs mn)	Revenue	YoY (%)	EBITDA	EBITDA (%)	Adj. PAT	YoY (%)	DEPS Rs.	RoE (%)	RoCE (%)	P/E (x)	EV/EBITDA (x)
FY16	1,39,552	15.1	31,877	22.8	20,232	28.4	34.5	31.9	19.9	21.5	14.8
FY17	1,50,898	8.1	34,342	22.8	23,013	13.7	39.3	27.6	19.7	19.0	13.5
FY18	1,64,999	9.3	37,886	23.0	24,229	5.3	41.3	23.0	17.3	16.2	11.2
FY19E	1,93,593	17.3	45,988	23.8	28,978	19.6	49.4	22.3	17.1	10.8	7.4
FY20E	2,24,510	16.0	54,560	24.3	34,760	20.0	59.3	21.9	17.7	9.0	6.2

Source: Company, Centrum Research Estimates

In the interest of timeliness, this document is not edited¹

Centrum Equity Research is available on Bloomberg, Thomson Reuters and FactSet

Target Price	Rs1,070	Key Data	
CMP*	Rs535	Bloomberg Code	ARBP IN
Upside	99.9%	Curr Shares O/S (mn)	585.9
Previous Target	Rs1,170	Diluted Shares O/S(mn)	585.9
Previous Rating	Buy	Mkt Cap (Rsbn/USDbn)	313.6/4.7
Price Performance (%)*		52 Wk H / L (Rs)	809.5/527
		5 Year H / L (Rs)	895/69.2
ARBP IN	(12.6)	Daily Vol. (3M NSE Avg.)	2396803
Nifty	0.1		


*as on 1st June 2018 Source: Bloomberg, Centrum Research

Shareholding pattern (%)*

	Mar-18	Dec-17	Sept-17	June-17
Promoter	51.9	51.9	51.9	51.9
FIs	18.0	18.9	18.8	19.6
DIs	15.7	15.6	15.3	14.2
Others	14.4	13.6	14.0	14.3

Source: BSE, *as on 1st June 2018

Trend in EBITDA margin (%)



Source: Company, Centrum Research

Earning Revision

Particulars (Rs mn)	FY19E			FY20E		
	New	Old	Chg (%)	New	Old	Chg (%)
Sales	1,93,593	1,97,379	(1.9)	2,24,510	2,17,795	3.1
EBITDA	45,988	50,094	(8.2)	54,560	56,705	(3.8)
EBITDA Margin (%)	23.8	25.4	(160)bps	24.3	26.0	(170)bps
PAT	28,978	33,484	(13.5)	34,760	37,965	(8.4)

Source: Centrum Research Estimates

Centrum vs. Bloomberg Consensus*

Particulars (Rs mn)	FY19E			FY20E		
	Centrum	BBG	Var (%)	Centrum	BBG	Var (%)
Sales	1,93,593	1,80,833	7.1	2,24,510	1,97,614	13.6
EBITDA	45,988	41,485	10.9	54,560	45,428	20.1
PAT	28,978	26,523	9.3	34,760	29,241	18.9

Bloomberg Consensus*				Centrum Target Price (Rs)	Variance (%)
BUY	SELL	HOLD	Target Price (Rs)		
38	1	3	755	1,070	41.7

*as on 8th February 2018 Source: Bloomberg, Centrum Research

Ranjit Kapadia, ranjit.kapadia@centrum.co.in; 91 22 4215 9645

Concall highlights

Major products and key markets

- As per the management, the US growth of 9%YoY during FY18 was due to new product launches and volume growth of existing products.
- The management informed that the company filed 11 ANDAs in Q4FY18 and has received 10 ANDA approvals from US FDA.
- The management indicated receipt of EIR for unit IV and Unit XII from US FDA.
- APL witnessed 1% QoQ price erosion in the base business in US in Q4FY18. The management expects price erosion of ~5% in FY19.
- The management indicated that 83 products of Actavis have been site transferred to Vizag, and plans to transfer total 112 products to Vizag.
- APL plans to launch differentiated products in the US with new launches across oncology, microsphere, peptide, liposomal, hormones, oral contraceptives, depot injections and complex substance filings. The upside from these businesses is expected from FY19 onwards.
- APL is the leading player in ARV and faces limited competition due to few players in this space. The decline in revenues by 43%YoY was due to the absence of profitable tenders. The management indicated the launch of combination product in FY19.
- The management expects 30-40 product launches in the US in FY19 of which 10 are approved.

US FDA approvals and new product launches

- For Q4FY18, the management indicated \$35mn (Rs2.38bn) revenues from the injectable business in US. APL has filed 90 ANDAs for injectables with US FDA of which 57 ANDAs are approved.
- APL filed 478 ANDAs with US FDA, of which 361 have been approved and 117 are pending approval. Hence, it has a rich product pipeline for the US market. The company has received tentative approvals for 34 ANDAs.
- APL has filed 227 DMFs with US FDA till date and filed 1 DMFs in Q4FY18.
- As per the management, the pricing pressure in the US business was partially offset by new product launches, volume growth of existing products and growth in Natrol products.
- The management has indicated the launch of Nexium and omeprazole OTC products in the US market. It has addressable market of \$70mn (Rs4.8bn).

Financials

- The management indicated a net debt of \$538mn (Rs36.6bn) by the end of Q4FY18. Majority of the debt is in foreign currency. The rise in debt was attributed to the launch of high cost products in the US, increase in working capital on GST implementation and Portugal acquisition. The average interest cost ~2% as per the management.
- The management expects \$100mn (Rs6.8bn) debt reduction in FY19.
- Forex loss was Rs159mn in Q4FY18 as against a forex gain of Rs73mn a year ago.
- The management has guided for R&D expenses of ~5% of revenues during FY19. The same was Rs1.87bn or 4.0% in Q4FY18.
- The management indicated capex of \$175mn (Rs11.90bn) in FY19.
- The management has guided tax rate of 26.5% for FY18 and 24.5-25.5% for FY19.

Sales Composition

APL's revenue grew 11%YoY to Rs40.49bn in Q4FY18 from Rs36.42bn a year ago, led by 13%YoY growth in its formulations business. APL's formulations business (80% of revenues) grew by 13% YoY to Rs32.49bn from Rs28.79bn due to the good growth across geographies. Formulation sales in the US (43% of revenues) grew by 6%YoY despite pricing pressure in the US generic market. Formulations sales in the EU (28% of revenues) grew by 48% YoY to Rs11.52bn from Rs7.77bn due to integration of Portugal acquisition from May'17 and strong growth in Germany, UK, France and Spain. APL's ARV formulations business (5% of revenues) declined by 43% YoY due to lack of profitable tenders and pricing pressure.

The company's API business (20% of revenues) grew by 5%YoY to Rs7.99bn from Rs7.63bn due to the impact of GST in the domestic market. The vertical integration of in-house APIs stood at ~70%.

The major growth is likely to come from US , Europe and RoW markets.

The details of sales composition in Q4FY18 are as follows:

Exhibit 1: Sales composition

Particulars (Rs mn)	Q4FY18	Q4FY17	YoY (%)	Q3FY18	QoQ (%)	Q4FY18E	% Var.
FORMULATIONS							
Formulations-USA	17,388	16,432	5.8	19,096	(8.9)	18,000	(3.4)
Formulations-EU	11,516	7,772	48.2	11,716	(1.7)	11,300	1.9
Formulations- ROW	2,096	1,971	6.3	2,502	(16.2)	2,700	(22.4)
Formulations-ARV	1,486	2,619	(43.3)	2,389	(37.8)	2,600	(42.8)
Formulations-total	32,486	28,794	12.8	35,703	(9.0)	34,600	(6.1)
API							
API-Betalactum	5,327	5,121	4.0	5,366	(0.7)	5,500	(3.1)
API- Non betalactum	2,669	2,506	6.5	2,292	16.4	2,400	11.2
API-Total	7,996	7,627	4.8	7,658	4.4	7,900	1.2
Dossier income	8	(6)	NA	1	NA	2	300.0
Total income	40,490	36,415	11.2	43,362	(6.6)	42,502	(4.7)

Source: Company, Centrum Research

Acquisitions well- integrated

The Actavis generics business in Europe and Natrol nutraceutical business in the US are well integrated with APL and are performing well. The Actavis business reported double-digit margin during Q4FY18. APL has site transferred 83 products from Europe to Vizag for cost optimisation. APL has plans to overall transfer 112 products from Europe to India under site transfer.

Natrol is expected to grow at a 15% CAGR over the next two to three years and has margin higher than the average company margin. The company has plans to expand the product portfolio of Natrol and export Natrol brands to other countries. APL has completed the acquisition of the Portugal based company Generis Farmaceutica SA during FY18. With this acquisition, APL has become the No.1 Company in the Portuguese generic market. It has merged the operations of three Portuguese subsidiaries for cost optimisation.

We expect APL to report good performance, driven by good growth in the US market from injectable business, new ANDA approvals and volume growth in existing products. APL has one of the largest basket of injectable products. We have revised our FY19E and FY20E EPS by 14% and 9% respectively. At the CMP of Rs535, the stock trades at 10.8x FY19E EPS of Rs49.4 and 9.0x FY20E EPS of Rs59.3. We maintain our Buy rating on the scrip, with a revised TP of Rs1,070 based on 18x March'20E EPS of Rs59.3, and with an upside of 99.9% from CMP. Key risks to our assumptions include slower growth in the US business and regulatory risks for its manufacturing facilities. APL is among our top picks in the pharma sector.

Earning Revision

Based on the Q4FY18 and FY18 we have revised our FY19E and FY20E EPS downwards by 14% and 8% respectively as follows:

Exhibit 2: Earning Revision

Particulars	FY19E			FY20E		
	Current	Earlier	Chg(%)	Current	Earlier	Chg(%)
Sales	1,93,593	1,97,379	(1.9)	2,24,510	2,17,795	3.1
EBIDTA	45,988	50,094	(8.2)	54,560	56,705	(3.8)
EBIDTA margin (%)	23.8	25.4	(160)bps	24.3	26.0	(170)bps
Net profit	28,978	33,484	(13.5)	34,760	37,965	(8.4)

Source: Centrum Research Estimates


Valuation

Exhibit 3: Sensitivity Analysis

Sensitivity to key variables – FY19E	% change	% impact on EBITDA	% impact on EPS
Sales	1	4.2	6.7
Material cost	1	(1.7)	(2.7)


Source: Company, Centrum Research Estimates

Exhibit 4: 1 year forward EV/EBITDA chart



Source: Bloomberg, Company, Centrum Research Estimates

Exhibit 5: 1 year forward P/E chart



Source: Bloomberg, Company, Centrum Research Estimates

Exhibit 6: Comparative Valuations

Sector	Mkt Cap (Rs mn)	CAGR FY17-FY19E (%)			EBITDA Margin (%)			PE (x)			EV/EBITDA (x)			RoE (%)			Div Yield (%)		
		Rev.	EBITDA	PAT	FY17	FY18	FY19E	FY17	FY18	FY19E	FY17	FY18	FY19E	FY17	FY18	FY19E	FY17	FY18	FY19E
Aurobindo	3,13,510	13.3	15.7	12.2	22.8	23.0	23.8	19.0	16.2	10.8	13.5	11.2	7.4	27.6	23.0	22.3	0.4	0.3	0.8
Cipla	4,22,625	9.6	19.0	34.6	16.9	18.6	20.0	42.9	31.1	22.5	18.9	17.1	12.6	8.6	10.6	12.5	0.4	0.6	0.8
Dr. Reddy's Labs	3,22,206	3.9	3.7	(2.6)	17.4	16.5	17.3	39.6	41.9	26.3	22.7	18.9	13.8	10.4	7.6	9.5	0.8	1.0	1.5
Lupin	3,45,328	(1.8)	(12.3)	(22.2)	25.7	19.9	20.5	26.8	26.6	22.3	16.8	16.2	11.6	20.7	1.9	10.9	0.6	0.6	0.9

Source: Company, Centrum Research Estimates Prices as on 1st June 2018

Quarterly financials, Operating Metrics and Key Performance Indicators

Exhibit 7: Quarterly Financials -consolidated

PARTICULARS (Rs mn)	Q1FY17	Q2FY17	Q3FY17	Q4FY17	Q1FY18	Q2FY18	Q3FY18	Q4FY18
P & L								
Revenues	37,666	37,755	39,062	36,416	36,788	44,359	43,361	40,491
Material cost	16,370	15,848	17,097	15,028	14,978	17,679	18,175	16,694
Personnel expenses	4,321	4,266	4,456	4,635	4,902	5,187	5,407	5,813
Other Expenses	8,086	8,349	8,560	9,541	8,492	10,319	9,524	9,943
Total Expenses	28,777	28,463	30,113	29,204	28,372	33,185	33,106	32,450
EBIDTA	8,889	9,292	8,949	7,212	8,416	11,174	10,255	8,041
Other income	159	83	79	218	221	103	331	438
PBDIT	9,048	9,375	9,028	7,430	8,637	11,277	10,586	8,479
Interest	206	175	143	143	169	173	189	247
Depreciation	1062	1102	1111	1001	1312	1321	1381	1566
Forex gain /(loss)	70	202	158	190	(77)	(4)	-	(159)
Profit before tax	7,850	8,300	7,932	6,476	7,079	9,779	9,016	6,507
Tax provision	2008	2240	2177	1171	1910	1980	3069	1224
Net profit before minority	5,842	6,060	5,755	5,305	5,169	7,799	5,947	5,283
Share of profit of JV	7	(4)	31	19	15	13	3	3
Net profit	5,849	6,056	5,786	5,324	5,184	7,812	5,950	5,286
Growth (%)								
Revenues	14.2	12.2	11.4	(2.8)	(2.3)	17.5	11.0	11.2
EBIDTA	22.6	19.3	9.4	(16.8)	(5.3)	20.3	14.6	11.5
Net profit	23.8	33.5	6.3	(4.0)	(11.4)	29.0	2.8	(0.7)
Margin (%)								
EBIDTA	23.6	24.6	22.9	19.8	22.9	25.2	23.7	19.9
Profit before tax	20.8	22.0	20.3	17.8	19.2	22.0	20.8	16.1
Net margin before EO	15.5	16.0	14.8	14.6	14.1	17.6	13.7	13.1

Source: Company, Centrum Research

Exhibit 8: Key performance indicators

Key performance indicator	FY16	FY17	FY18	FY19E	FY20E
Sales Growth %	15.1	8.1	9.3	17.3	16.0
Material cost %	44.2	42.6	40.9	40.5	40.4

Source: Centrum Research Estimates

Financials -consolidated

Exhibit 9: Income Statement

Y/E March (Rs mn)	FY16	FY17	FY18	FY19E	FY20E
Revenues	1,39,552	1,50,898	1,64,999	1,93,593	2,24,510
Material cost	61,622	64,342	67,528	78,325	90,620
% of revenues	44.2	42.6	40.9	40.5	40.4
Employee cost	15,427	17,678	21,308	25,230	28,870
% of revenues	11.1	11.7	12.9	13.0	12.9
Other Expenses	30,626	34,536	38,277	44,050	50,460
% of revenues	21.9	22.9	23.2	22.8	22.5
EBIDTA	31,877	34,342	37,886	45,988	54,560
EBIDTA margin (%)	22.8	22.8	23.0	23.8	24.3
Depreciation & Amortisation	3,923	4,276	5,580	6,050	6,550
EBIT	27,954	30,066	32,306	39,938	48,010
Interest Expenses	927	667	777	930	1,050
PBT from operations	27,027	29,399	31,529	39,008	46,960
Other income	399	1,160	852	1,200	1,400
PBT	27,426	30,559	32,381	40,208	48,360
Tax provision	7,208	7,596	8,183	11,270	13,650
Effective tax rate (%)	26.3	24.9	25.3	28.0	28.2
Net profit	20,218	22,963	24,198	28,938	34,710
Minority interest	14	50	31	40	50
Reported net profit	20,232	23,013	24,229	28,978	34,760
Adj. Net profit	20,232	23,013	24,229	28,978	34,760

Source: Company, Centrum Research Estimates

Exhibit 10: Key Ratios

Y/E March (Rs mn)	FY16	FY17	FY18	FY19E	FY20E
Growth Ratios (%)					
Revenues	15.1	8.1	9.3	17.3	16.0
EBIDTA	24.3	7.7	10.3	21.4	18.6
Adj. Net Profit	28.4	13.7	5.3	19.6	20.0
Margin Ratios (%)					
EBIDTA margin	22.8	22.8	23.0	23.8	24.3
PBT from operations margin	19.4	19.5	19.1	20.1	20.9
Adj. PAT margin	14.5	15.3	14.7	15.0	15.5
Return Ratios (%)					
RoCE	19.9	19.7	17.3	17.1	17.7
RoE	31.9	27.6	23.0	22.3	21.9
RoIC	20.9	20.0	18.0	17.9	18.5
Turnover ratios (days)					
Gross Block Turnover (x)	3.2	3.5	3.1	3.1	3.0
Debtors	120	67	68	72	67
Creditors	67	62	59	93	96
Inventory	106	105	130	114	126
Cash Conversion Cycle	160	110	139	93	98
Solvency Ratio					
Debt-Equity	0.6	0.3	0.4	0.3	0.2
Net Debt-Equity	0.5	0.3	0.3	0.2	0.1
Current Ratio	2.5	2.6	2.7	2.7	2.7
Interest Coverage Ratio	0.0	0.0	0.0	0.0	0.0
Gross Debt/EBIDTA	1.4	0.9	1.2	0.9	0.7
Per Share (Rs)					
FDEPS (adjusted)	34.5	39.3	41.3	49.4	59.3
CEPS	41.2	46.6	50.9	59.8	70.5
Book Value	124.6	159.9	199.3	244.0	297.4
Dividend	2.3	1.9	3.5	4.0	5.0
Dividend Payout (%)	7.7	7.0	5.7	8.4	8.0
Valuations (x) (Avg Mkt Cap)					
PER	21.5	19.0	16.2	10.8	9.0
P/BV	6.0	4.7	3.4	2.2	1.8
EV/EBIDTA	14.8	13.5	11.2	7.4	6.2
Dividend Yield (%)	0.4	0.4	0.3	0.8	0.9
5-yr Avg AOCF/EV yield(%)	1.6	2.8	3.9	6.0	6.9

Source: Company, Centrum Research Estimates

Exhibit 11: Balance Sheet

Y/E March (Rs mn)	FY16	FY17	FY18	FY19E	FY20E
Share capital	585	586	586	586	586
Reserves & surplus	72,290	93,133	1,16,218	1,42,406	1,73,683
Total shareholders Funds	72,875	93,719	1,16,804	1,42,992	1,74,269
Total Debt	44,155	30,841	44,825	40,800	39,200
Minority interest	26	21	18	16	15
Deferred tax Liab.	(1,823)	(1,185)	765	1,040	1,350
Total Liabilities	1,15,233	1,23,396	1,62,412	1,84,848	2,14,834
Gross Block	37,259	47,998	58,219	67,521	80,521
Less: Acc. Depreciation	3,457	7,168	10,854	14,589	18,689
Net Block	33,802	40,830	47,366	52,932	61,833
Capital WIP	8,481	14,581	15,830	17,700	19,500
Intangible assets	7,994	7,508	17,840	18,200	18,825
Net Fixed Assets	50,277	62,919	81,036	88,832	1,00,158
Investments	1,229	2,459	3,115	8,500	10,700
Inventories	40,562	43,305	58,584	60,700	77,600
Debtors	46,067	27,653	30,844	38,000	41,500
Loans & Advances	3,229	11,210	156	250	300
Cash & Bank Balance	8,003	5,135	12,616	13,466	14,376
Other assets	7,775	8,136	23,113	26,700	31,500
Total Current Assets	1,05,636	95,439	1,25,313	1,39,116	1,65,276
Trade payable	25,479	25,523	26,705	49,500	59,000
Other current Liabilities	15,687	11,040	17,778	-	-
Provisions	743	858	2,568	2,100	2,300
Net Current Assets	63,727	58,018	78,262	87,516	1,03,976
Total Assets	1,15,233	1,23,396	1,62,412	1,84,848	2,14,834

Source: Company, Centrum Research Estimates

Exhibit 12: Cash Flow

Y/E March (Rs mn)	FY16	FY17	FY18	FY19E	FY20E
CF before WC changes	24,979	27,597	32,233	35,777	42,094
Working Capital Changes	(7,383)	2,841	(12,763)	(8,404)	(15,550)
CF from Operations	17,596	30,438	19,470	27,373	26,544
Adj OCF (OCF-Interest)	16,669	29,771	18,693	26,443	25,494
Addition of Fixed Assets	(15,492)	(17,404)	(13,365)	(13,487)	(17,251)
Adj. FCF (AOCF-Capex)	1,176	12,367	5,329	12,956	8,244
CF from Investing	(13,763)	(18,153)	(24,356)	(19,234)	(20,077)
CF from Financing	(198)	(14,686)	11,543	(6,814)	(5,088)
Net change in Cash	3,635	(2,401)	6,658	1,325	1,380

Source: Company, Centrum Research Estimates

Appendix A

Disclaimer

Centrum Broking Limited ("Centrum") is a full-service, Stock Broking Company and a member of The Stock Exchange, Mumbai (BSE) and National Stock Exchange of India Ltd. (NSE). Our holding company, Centrum Capital Ltd, is an investment banker and an underwriter of securities. As a group Centrum has Investment Banking, Advisory and other business relationships with a significant percentage of the companies covered by our Research Group. Our research professionals provide important inputs into the Group's Investment Banking and other business selection processes.

Recipients of this report should assume that our Group is seeking or may seek or will seek Investment Banking, advisory, project finance or other businesses and may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of this material/report. Our Company and Group companies and their officers, directors and employees, including the analysts and others involved in the preparation or issuance of this material and their dependants, may on the date of this report or from, time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. Centrum or its affiliates do not own 1% or more in the equity of this company. Our sales people, dealers, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We may have earlier issued or may issue in future reports on the companies covered herein with recommendations/ information inconsistent or different those made in this report. In reviewing this document, you should be aware that any or all of the foregoing, among other things, may give rise to or potential conflicts of interest. We and our Group may rely on information barriers, such as "Chinese Walls" to control the flow of information contained in one or more areas within us, or other areas, units, groups or affiliates of Centrum. Centrum or its affiliates do not make a market in the security of the company for which this report or any report was written. Further, Centrum or its affiliates did not make a market in the subject company's securities at the time that the research report was published.

This report is for information purposes only and this document/material should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. It is for the general information of the clients of Centrum. Though disseminated to clients simultaneously, not all clients may receive this report at the same time. Centrum will not treat recipients as clients by virtue of their receiving this report. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Similarly, this document does not have regard to the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this report may not be suitable for all investors. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. Persons who may receive this document should consider and independently evaluate whether it is suitable for his/ her/their particular circumstances and, if necessary, seek professional/financial advice. Any such person shall be responsible for conducting his/her/their own investigation and analysis of the information contained or referred to in this document and of evaluating the merits and risks involved in the securities forming the subject matter of this document.

The projections and forecasts described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. Projections and forecasts are necessarily speculative in nature, and it can be expected that one or more of the estimates on which the projections and forecasts were based will not materialize or will vary significantly from actual results, and such variances will likely increase over time. All projections and forecasts described in this report have been prepared solely by the authors of this report independently of the Company. These projections and forecasts were not prepared with a view toward compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these projections or forecasts. You should not regard the inclusion of the projections and forecasts described herein as a representation or warranty by or on behalf of the Company, Centrum, the authors of this report or any other person that these projections or forecasts or their underlying assumptions will be achieved. For these reasons, you should only consider the projections and forecasts described in this report after carefully evaluating all of the information in this report, including the assumptions underlying such projections and forecasts.

The price and value of the investments referred to in this document/material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. Future returns are not guaranteed and a loss of original capital may occur. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Centrum does not provide tax advice to its clients, and all investors are strongly advised to consult regarding any potential investment. Centrum and its affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk. Certain transactions including those involving futures, options, and other derivatives as well as non-investment-grade securities give rise to substantial risk and are not suitable for all investors. Please ensure that you have read and understood the current risk disclosure documents before entering into any derivative transactions.

This report/document has been prepared by Centrum, based upon information available to the public and sources, believed to be reliable. No representation or warranty, express or implied is made that it is accurate or complete. Centrum has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The opinions expressed in this document/material are subject to change without notice and have no obligation to tell you when opinions or information in this report change.

This report or recommendations or information contained herein do/does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced, transmitted or published by the recipient. The report is for the use and consumption of the recipient only. This publication may not be distributed to the public used by the public media without the express written consent of Centrum. This report or any portion hereof may not be printed, sold or distributed without the written consent of Centrum.

The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Neither Centrum nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

This document does not constitute an offer or invitation to subscribe for or purchase or deal in any securities and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. This document is strictly confidential and is being furnished to you solely for your information, may not be distributed to the press or other media and may not be reproduced or redistributed to any other person. The distribution of this report in other jurisdictions may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. By accepting this report, you agree to be bound by the foregoing limitations. No representation is made that this report is accurate or complete.

The opinions and projections expressed herein are entirely those of the author and are given as part of the normal research activity of Centrum Broking and are given as of this date and are subject to change without notice. Any opinion estimate or projection herein constitutes a view as of the date of this report and there can be no assurance that future results or events will be consistent with any such opinions, estimate or projection.

This document has not been prepared by or in conjunction with or on behalf of or at the instigation of, or by arrangement with the company or any of its directors or any other person. Information in this document must not be relied upon as having been authorized or approved by the company or its directors or any other person. Any opinions and projections contained herein are entirely those of the authors. None of the company or its directors or any other person accepts any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

Centrum and its affiliates have not managed or co-managed a public offering for the subject company in the preceding twelve months. Centrum and affiliates have not received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for service in respect of public offerings, corporate finance, debt restructuring, investment banking or other advisory services in a merger/acquisition or some other sort of specific transaction.

As per the declarations given by them, Mr. Ranjit Kapadia, research analyst and and/or any of his family members do not serve as an officer, director or any way connected to the company/companies mentioned in this report. Further, as declared by him, he has not received any compensation from the above companies in the preceding twelve months. He does not hold any shares by him or through his relatives or in case if holds the shares then will not to do any transactions in the said scrip for 30 days from the date of release such report. Our entire research professionals are our employees and are paid a salary. They do not have any other material conflict of interest of the research analyst or member of which the research analyst knows of has reason to know at the time of publication of the research report or at the time of the public appearance.

While we would endeavour to update the information herein on a reasonable basis, Centrum, its associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Centrum from doing so.

Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Centrum policies, in circumstances where Centrum is acting in an advisory capacity to this company, or any certain other circumstances.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Centrum Broking Limited or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market.

Aurobindo Pharma price chart



Source: Bloomberg, Centrum Research

Disclosure of Interest Statement

1	Business activities of Centrum Broking Limited (CBL)	Centrum Broking Limited (hereinafter referred to as "CBL") is a registered member of NSE (Cash, F&O and Currency Derivatives Segments), MCX-SX (Currency Derivatives Segment) and BSE (Cash segment), Depository Participant of CDSL and a SEBI registered Portfolio Manager.
2	Details of Disciplinary History of CBL	CBL has not been debarred/ suspended by SEBI or any other regulatory authority from accessing /dealing in securities market.
3	Registration status of CBL:	Ranjit Kapadia is registered with SEBI as a Research Analyst (SEBI Registration No. INH000001352)

		Aurobindo	Cipla	Dr. Reddy's Labs	Lupin
4	Whether Research analyst's or relatives' have any financial interest in the subject company and nature of such financial interest	No	No	No	No
5	Whether Research analyst or relatives have actual / beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the document.	No	No	No	No
6	Whether the research analyst or his relatives has any other material conflict of interest	No	No	No	No
7	Whether research analyst has received any compensation from the subject company in the past 12 months and nature of products / services for which such compensation is received	No	No	No	No
8	Whether the Research Analyst has received any compensation or any other benefits from the subject company or third party in connection with the research report	No	No	No	No
9	Whether Research Analysts has served as an officer, director or employee of the subject company	No	No	No	No
10	Whether the Research Analyst has been engaged in market making activity of the subject company.	No	No	No	No

Rating Criteria

Rating	Market cap < Rs20bn	Market cap > Rs20bn but < 100bn	Market cap > Rs100bn
Buy	Upside > 20%	Upside > 15%	Upside > 10%
Hold	Upside between -20% to +20%	Upside between -15% to +15%	Upside between -10% to +10%
Sell	Downside > 20%	Downside > 15%	Downside > 10%

Member (NSE and BSE)

Regn No.:

CAPITAL MARKET SEBI REGN. NO.: BSE: INB011454239
CAPITAL MARKET SEBI REGN. NO.: NSE: INB231454233
DERIVATIVES SEBI REGN. NO.: NSE: INF231454233
(TRADING & CLEARING MEMBER)
CURRENCY DERIVATIVES: MCX-SX INE261454230
CURRENCY DERIVATIVES:NSE (TM & SCM) – NSE 231454233

Depository Participant (DP)

CDSL DP ID: 120 – 12200
SEBI REGD NO. : CDSL : IN-DP-CDSL-661-2012

PORTFOLIO MANAGER

SEBI REGN NO.: INP000004383

Website: www.centrum.co.in

Investor Grievance Email ID: investor.grievances@centrum.co.in

Compliance Officer Details:

Kavita Ravichandran
(022) 4215 9842; Email ID: Compliance@centrum.co.in

Centrum Broking Ltd. (CIN :U67120MH1994PLC078125)

Registered Office Address	Corporate Office & Correspondence Address
Bombay Mutual Building , 2nd Floor, Dr. D. N. Road, Fort, Mumbai - 400 001	Centrum House 6th Floor, CST Road, Near Vidya Nagari Marg, Kalina, Santacruz (E), Mumbai 400 098. Tel: (022) 4215 9000